AGN 2.70% 76.0¢ argenica therapeutics limited

Ann: Successful Completion of Phase 1 Clinical Trial Dosing, page-24

  1. 9,854 Posts.
    lightbulb Created with Sketch. 980
    Complete lack of buyers.
    The biotech space has been hammered the last year.
    Sentiment is abysmal. AGN has not been able to shake off the biotech stink even with a seemingly fantastic Phase 1 trial result.

    Sentiment is due to turn and AGN will be a big beneficiary when it does.

    Im holding on.
 
watchlist Created with Sketch. Add AGN (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.